Shanghai Alice Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that AST2303 tablets were approved for drug clinical trials
Announcement of Shanghai Alice Pharmaceutical Technology Co., Ltd. on participating in the 2024 Semi-Annual Science and Technology Innovation Board Special Group Performance Briefing on Pharmaceuticals and Biological Products
Shanghai Alice Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (August 2024)
Half-year evaluation report on the company's 'Improving Quality and Efficiency, Returning to Growth' action plan for 2024 by Shanghai Allist Pharmaceuticals Co., Ltd.
Shanghai Allist Pharmaceuticals Co., Ltd. Second Supervisory Board, Eighth Meeting Resolution Announcement.
Shanghai Allist Pharmaceuticals Co., Ltd.'s Special Report on the Deposits and Actual Use of Funds Raised in the First Half of 2024.
Shanghai Allist Pharmaceuticals Co., Ltd. voluntarily disclosed an announcement regarding the approval of a new clinical trial of the drug registration certificate for Vandetanib's new indication.
Investor Relations Activity Log of Shanghai Allist Pharmaceuticals Co., Ltd. (July 2-4, 2024)
Investor relations activity record of Shanghai Allist Pharmaceuticals Co., Ltd. (June 20-21, 2024)
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Shanghai Alice Pharmaceutical Technology Co., Ltd.
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision Work Site Inspection Report on Shanghai Alice Pharmaceutical Technology Co., Ltd.
Shanghai Alice Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (April 26, 2024)
Announcement of Resolutions of the 7th Meeting of the 2nd Board of Supervisors of Shanghai Alice Pharmaceutical Technology Co., Ltd.
Announcement of Shanghai Alice Pharmaceutical Technology Co., Ltd. on determining the remaining use of funds raised in the original fund-raising project, closing some fund-raising projects, and using the savings raised for new drug research and development projects, supplementary working capital, and adjusting new drug research and development projects
Verification opinions of CITIC Securities Co., Ltd. on Shanghai Alice Pharmaceutical Technology Co., Ltd. determining the remaining use of funds raised in the original fund-raising project, closing some of the fund-raising projects, and using the savings raised for new drug development projects and supplementary working capital, and adjusting the new drug research and development projects
Shanghai Alice Pharmaceutical Technology Co., Ltd. assessment report on the performance of accounting firms in 2023
Shanghai Alice Pharmaceutical Technology Co., Ltd. 2023 Independent Director Debriefing Report (Lu Chao)
Shanghai Alice Pharmaceutical Technology Co., Ltd. 2023 Independent Director Debriefing Report (Yan Jun)
Shanghai Alice Pharmaceutical Technology Co., Ltd. 2023 Independent Director Debriefing Report (Zhu Shengtao)
Special Report on Capital Occupation by Controlling Shareholders and Other Related Parties in 2023 of Shanghai Alice Pharmaceutical Technology Co., Ltd.
No Data
No Data